Press Releases

First patient dosed in global study of oral α4β7 integrin inhibitor WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a

Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical

Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the

Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral

200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical

Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders Founder, Director, and Scientific Advisory Board member of Morphic Therapeutic WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a

Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:

WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside

Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6 million in cash and equivalents Cash runway extended into second half of 2025 WALTHAM, Mass. , Aug.